Posted by Michael Wonder on 04 Dec 2025
Hope Medicine's HMI-115 received US FDA fast track designation, accelerating global development
4 December 2025 - Hope Medicine today announced that its lead pipeline product, HMI-115, a monoclonal antibody targeting the prolactin receptor, has been granted fast track designation by the US FDA for the treatment of moderate to severe pain associated with endometriosis.
The granting of fast track designation was based on the results of a completed global Phase 2 clinical trial for HMI-115.
